Journal of medical case reports · 2026
Vogt-Koyanagi-Harada-like uveitis with severe hyalitis during treatment by anti-programmed death 1 antibody for lung cancer: a case report.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liu Xuanli, Lu Yunfeng, Lu Peirong, Zhang Yunhai, Xia Wei
Аннотация
BACKGROUND: Vogt-Koyanagi-Harada-like uveitis that presents with severe hyalitis has rarely been reported during anti-programmed death 1 therapy.
CASE PRESENTATION: A 70-year-old Chinese man presented with bilateral visual disturbances and vomiting after four cycles of serplulimab, an anti-programmed death 1 antibody, for metastatic lung carcinoma. His best corrected visual acuity was measured at 0.04 in the right eye and 0.02 in the left eye. A slit-lamp examination indicated severe hyalitis, while ocular ultrasound revealed focal serous retinal detachment. Magnetic resonance imaging demonstrated choroidal thickening and cerebrospinal fluid analysis indicated a mild lymphocytic elevation. Retinal fluorescein angiography exhibited focal pinpoint leakage and delayed hyperfluorescence at the optic disc. A diagnosis of Vogt-Koyanagi-Harada-like uveitis secondary to anti-programmed death 1 therapy was established. Following the discontinuation of anti-programmed death 1 treatment and 1-month course of oral prednisone at a dosage of 40 mg per day, the patient's best corrected visual acuity improved to 0.6 in the right eye and 0.4 in the left eye.
CONCLUSION: Corticosteroid treatment has proven effective for Vogt-Koyanagi-Harada-like uveitis. Currently, the optimal mode and dosage of corticosteroid therapy have not been clearly defined. Gathering more real-world cases of Vogt-Koyanagi-Harada-like uveitis associated with anti-programmed death 1 antibodies would be beneficial in developing therapeutic guidelines.
CASE PRESENTATION: A 70-year-old Chinese man presented with bilateral visual disturbances and vomiting after four cycles of serplulimab, an anti-programmed death 1 antibody, for metastatic lung carcinoma. His best corrected visual acuity was measured at 0.04 in the right eye and 0.02 in the left eye. A slit-lamp examination indicated severe hyalitis, while ocular ultrasound revealed focal serous retinal detachment. Magnetic resonance imaging demonstrated choroidal thickening and cerebrospinal fluid analysis indicated a mild lymphocytic elevation. Retinal fluorescein angiography exhibited focal pinpoint leakage and delayed hyperfluorescence at the optic disc. A diagnosis of Vogt-Koyanagi-Harada-like uveitis secondary to anti-programmed death 1 therapy was established. Following the discontinuation of anti-programmed death 1 treatment and 1-month course of oral prednisone at a dosage of 40 mg per day, the patient's best corrected visual acuity improved to 0.6 in the right eye and 0.4 in the left eye.
CONCLUSION: Corticosteroid treatment has proven effective for Vogt-Koyanagi-Harada-like uveitis. Currently, the optimal mode and dosage of corticosteroid therapy have not been clearly defined. Gathering more real-world cases of Vogt-Koyanagi-Harada-like uveitis associated with anti-programmed death 1 antibodies would be beneficial in developing therapeutic guidelines.